mp-dLAE-PABC-MMAE

• UNSPSC Description:

  mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs)[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mp-dlae-pabc-mmae.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N([C@H]([C@@H](CC(N1[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@@H](O)C2=CC=CC=C2)C)=O)C)CCC1)=O)OC)[C@@H](C)CC)C)=O)=O)OCC3=CC=C(NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@@H](CC(C)C)NC(CCN4C(C=CC4=O)=O)=O)=O)=O)=O)C=C3

• Molecular Weight:

  1331.59

• References & Citations:

  [1]Sandall Sharsti and Waight Andrew. Engineering of anti-CD228 antibodies and antibody-drug conjugates for cancer immunotherapy. WO2022031652. 2022.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2625616-44-4